- Home
- TROO vs AVIR Comparison
TROO vs AVIR Comparison
Compare TROO & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TROO
- AVIR
- Stock Information
- Founded
- TROO 2005
- AVIR 2012
- Country
- TROO Hong Kong
- AVIR United States
- Employees
- TROO N/A
- AVIR N/A
- Industry
- TROO Radio And Television Broadcasting And Communications Equipment
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- TROO Technology
- AVIR Health Care
- Exchange
- TROO Nasdaq
- AVIR Nasdaq
- Market Cap
- TROO 215.4M
- AVIR 290.4M
- IPO Year
- TROO N/A
- AVIR 2020
- Fundamental
- Price
- TROO $2.13
- AVIR $3.56
- Analyst Decision
- TROO
- AVIR Hold
- Analyst Count
- TROO 0
- AVIR 1
- Target Price
- TROO N/A
- AVIR $6.88
- AVG Volume (30 Days)
- TROO 11.0K
- AVIR 152.3K
- Earning Date
- TROO 10-29-2024
- AVIR 11-06-2024
- Dividend Yield
- TROO N/A
- AVIR N/A
- EPS Growth
- TROO N/A
- AVIR N/A
- EPS
- TROO N/A
- AVIR N/A
- Revenue
- TROO $3,569,000.00
- AVIR N/A
- Revenue This Year
- TROO N/A
- AVIR N/A
- Revenue Next Year
- TROO N/A
- AVIR N/A
- P/E Ratio
- TROO N/A
- AVIR N/A
- Revenue Growth
- TROO N/A
- AVIR N/A
- 52 Week Low
- TROO $0.73
- AVIR $2.77
- 52 Week High
- TROO $4.89
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- TROO 31.08
- AVIR 49.38
- Support Level
- TROO $2.11
- AVIR $3.31
- Resistance Level
- TROO $2.29
- AVIR $3.86
- Average True Range (ATR)
- TROO 0.18
- AVIR 0.12
- MACD
- TROO -0.00
- AVIR 0.03
- Stochastic Oscillator
- TROO 4.13
- AVIR 46.90
About TROO TROOPS Inc.
TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).